Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 15/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23455815 | 1.00 | ATF4 (0.69) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL23455817 | 1.00 | ATF4 (0.69) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL16082976 | 0.93 | ATF4 (0.78) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL22614154 | 0.91 | ATF4 (0.72) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL21050157 | 0.91 | ATF4 (0.72) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL23455912 | 0.91 | ATF4 (0.65) | ATF4LMNA | |
| SCHEMBL23455910 | 0.91 | ATF4 (0.65) | ATF4LMNA | |
| SCHEMBL23455785 | 0.89 | ATF4 (0.61) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL23455784 | 0.89 | ATF4 (0.61) | ATF4LMNARAB9AHPGDHTT | |
| SCHEMBL24998317 | 0.89 | ATF4 (0.67) | ATF4LMNARAB9AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939320-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20210171508-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| CN-112166113-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939320-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | ATF4 1/4885LMNA 3376/4885RAB9A 2904/4885 |
| US-20210171508-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885LMNA 3376/4885RAB9A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.